Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Net Margin came in at 76.29% in Q1 2026, up 7542.0% YoY from 1.0% in Q1 2025, and down 18.96% on a QoQ basis from 64.13% in Q4 2025.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Net Margin data on file, last reported at 76.29% in Q1 2026.
- Quarterly Net Margin rose 7542.0% year-over-year to 76.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.56% (up 6001.0% YoY) and the FY2025 annual result came in at 125.36%, up 4622.0% from the prior year.
- Net Margin retreated to 76.29% in Q1 2026, from 64.13% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 64.13% in Q4 2025 to a low of 211.62% in Q1 2023.
- A 5-year average of 146.29% and a median of 135.14% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 21773 bps — and 2023, when it slumped 6266 bps.
- Tracing ENTA's Net Margin over 5 years: stood at 122.9% in 2022, then plunged by 51 bps to 185.56% in 2023, then advanced by 29 bps to 131.43% in 2024, then jumped by 51 bps to 64.13% in 2025, then decreased by 19 bps to 76.29% in 2026.
- The last three Net Margin figures came in at 76.29% (Q1 2026), 64.13% (Q4 2025), and 123.64% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Enanta Pharmaceuticals | 409.30 Mn | 219.79 Mn | - | -135.81% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -135.81% |
| Mar 31, 2026 | -76.29% |
| Dec 31, 2025 | -64.13% |
| Sep 30, 2025 | -122.90% |
| Jun 30, 2025 | -99.68% |
| Mar 31, 2025 | -151.71% |
| Dec 31, 2024 | -131.43% |
| Sep 30, 2024 | -196.00% |
| Jun 30, 2024 | -126.08% |
| Mar 31, 2024 | -182.70% |
| Dec 31, 2023 | -185.56% |
| Sep 30, 2023 | -148.46% |
| Jun 30, 2023 | -206.78% |
| Mar 31, 2023 | -211.62% |
| Dec 31, 2022 | -122.90% |
| Sep 30, 2022 | -129.61% |
| Jun 30, 2022 | -162.74% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -108.92% |
| Sep 30, 2021 | -103.76% |